ProSomnus Poised to Support Obstructive Sleep Apnea Patients Following Discontinuation of Philips Respironics OSA Devices - Seite 2

“As a DSM Specialist, the recent news of Philips Respironics exiting the U.S. sleep business represents a significant shift in the landscape of sleep health solutions and has important implications for both patients and healthcare providers,” stated Dr. Stacey Layman, D-ABDSM, D-ABSA. “Philips has been a prominent player in the sleep health industry, providing innovative solutions for sleep apnea and other sleep disorders. Their decision to withdraw from this market has led to a gap that needs to be filled. DSM is an emerging field focusing on the diagnosis and treatment of sleep-related breathing disorders through dental interventions. This transition underscores the significance of multi-disciplinary collaboration within sleep medicine. DSM specialists can work in tandem with sleep physicians and other healthcare providers to offer holistic, patient-centered care for individuals suffering from sleep-related issues. Oral Appliance Therapy has been demonstrated in clinical studies to be highly effective in managing sleep disorders, offering patients a non-invasive and comfortable alternative to traditional CPAP therapy. I encourage patients and healthcare providers to explore all treatment options for OSA.”

“ProSomnus qualified providers are already working alongside sleep physicians in utilizing precision Oral appliance Therapy (OAT) to treat OSA,” stated Dr. Mark T. Murphy, DDS D-ABDSM. “We expect that this Philips discontinuation is likely to create a supply chain issue with CPAP availability and affect access to care. ProSomnus is positioned to provide patients timely access to care with its clinically proven and patient preferred precision appliances.”

We invite patients and sleep physicians to contact ProSommus at [e-mail] to learn more about ProSomnus precision devices or to be introduced with a qualified provider in their area.

About ProSomnus
ProSomnus (NASDAQ: OSA) is the leading non-CPAP therapy for the treatment of Obstructive Sleep Apnea a serious medical disease affecting over 1 billion people worldwide, that is associated with comorbidities including heart failure, stroke, hypertension, morbid obesity, and type 2 diabetes. ProSomnus intraoral medical devices are engineered to precisely track the treatment plan and anatomy for each patient. Non-invasive, patient preferred and easy to use, ProSomnus devices have demonstrated excellent efficacy, safety, adherence, and overall outcomes in a growing body of clinical investigations. ProSomnus precision intraoral devices are FDA-cleared, patented, and covered by commercial medical insurance, Medicare, TRICARE and many Government-sponsored healthcare plans around the world, representing over 200 million covered lives. To learn more, visit www.ProSomnus.com.